Nemaura Medical Announces Interview with CEO to Air on May 11
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer markets, announced it is planning to launch a digital healthcare subscription service in the USA under the brand name proBEAT™.
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, announced it is preparing for the launch of sugarBEAT® in the U.S. under the wellness category following recent feedback from the U.S. Food and Drug Administration (the "FDA"). The Company is prioritizing launch plans in the U.S. and is considering various options to expedite the launch, including potential partnering in continuation of its on-going discussions with multi-national companies.
Loughborough, England, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a 2019 year-end corporate update. The company started the first phase of our commercial launch of sugarBEAT® in the United Kingdom with the first shipments of sugarBEAT® CGM devices to diabetic and pre-diabetic patients from whom positive user feedback has been received.
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer markets, announced positive initial user-volunteer data from its head-to-head comparison with a major incumbent CGM device.
Loughborough, England, Dec. 05, 2019 -- Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a.
Loughborough, England, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided an update regarding the commercial launch of SugarBEAT® and feedback from its first patient user experiences as presented at the recent symposia hosted by Nemaura at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona. Dr. Faz Chowdhury, Chief Executive Officer, discussed key milestones in the development and plans for the commercial rollout program for SugarBEAT® in the UK, Ireland, Germany and other key European markets following its recent CE mark approval in the European Union.
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-inv…
Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, launched its sugarBEAT® App for Android devices on the Play Store in preparation for the planned launch of the Company’s BEAT®diabetes subscription based service expected for next month.1
NEW YORK, May 14, 2020 /PRNewswire/ -- The wearable technology market is quickly evolving into a major tech segment thanks to a growing consumer market driven by the sales of smartwatches. A major segment of the wearable technology market is wearable medical …
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Announces Interview with CEO to Air on May 11
Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, announced it has entered in to multiple verbal non-binding agreements for sugarBEAT® with the aim of securing regional and global partnerships.
The company's continuous glucose monitor is a potential breakthrough in the diabetes diagnostics space, and also the reason why its stock has gained momentum Continue reading...
Loughborough, England, Nov. 11, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the second quarter ended September 30, 2019. Dr. Faz Chowdhury, CEO of Nemaura commented, “This has been an exciting period for Nemaura as we officially commenced the commercial rollout plans for SugarBEAT® following our recent CE approval. As the world’s first non-invasive, safe, needle-free CGM, SugarBEAT® is uniquely positioned to target the underserved $80 billion market for Type 2 diabetics and pre-diabetics.
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer mar…
The med-tech company is planning to launch a new digital health care subscription service Continue reading...
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), announced plans for a new product line by seeking to immediately repurpose sugarBEAT® as a CTM since its inbuilt temperature sensor is capable of continuously tracking body temperature through the skin. Nemaura is considering various options to expedite the launch of a CTM, including potential partnerships and direct to consumer sales.
NEW YORK, May 11, 2020 /PRNewswire/ -- Around the world, there is an increasing number of people who have been diagnosed with lifestyle-associated diseases, such as hypertension and diabetes, which has created the need to monitor their health on a regular bas…
The reverse split is expected to take effect at the market open on December 5, 2019. In accordance with the reverse split, each stockholder’s percentage ownership interest in Nemaura Medical remains unchanged. Any fractional shares resulting from the reverse stock split were rounded up to the nearest whole share of common stock.
Loughborough, England, Dec. 17, 2019 -- Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible.
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), today announced it has secured a 24-month, $5 million non-convertible loan. The loan does not include warrants or other equity securities.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
The Company announced a partnership with the award-winning UK-based company, Changing Health, to bring digital behavior programs to improve the management, reversal and prevention of Type 2 diabetes in multiple territories commencing with the United Kingdom and Ireland. Changing Health is a provider of digital coaching services to the National Health Service England, aimed at the prevention or reversal of Type 2 diabetes.
FDA feedback leads to continuous glucose monitor placement into the wellness device category New York, New York--(Newsfile Corp. - March 20, 2020) - Small Caps Daily recently published an article on Nemaura Medical, Inc. (NASDAQ: NMRD), after the Company's latest surge in press coverage, piqued the publication's interest. The media interest is warranted, as it surrounds the preparations for the launch of Nemaura Medical's non-invasive and flexible continuous glucose monitor ("CGM"), sugarBEAT® in the U.S., ...
Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced its 2020 Omnibus Incentive Plan ("Plan") was approved by shareholder vote at the Company’s Annual General Meeting on May 15, 2020. A maximum of 1,000,000 shares of Common Stock have been made available for Awards under the Plan.